{"denoms":[{"counts":[{"groupId":"BG000","value":"559"},{"groupId":"BG001","value":"578"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1137"}],"units":"Participants"}],"groups":[{"description":"Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"BG000","title":"Arm A: FOLFOX or FOLFIRI + Bevacizumab"},{"description":"Patients receive cetuximab 400mg/m\\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\\^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"BG001","title":"Arm B: FOLFOX or FOLFIRI + Cetuximab"},{"description":"Patients receive cetuximab 400mg/m\\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\\^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"BG002","title":"Arm C: FOLFOX or FOLFIRI + Cetuximab + Bevacizumab"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"21.8","upperLimit":"85","value":"59"},{"groupId":"BG001","lowerLimit":"20.8","upperLimit":"89.5","value":"59.2"},{"groupId":"BG003","lowerLimit":"20.8","upperLimit":"89.5","value":"59.1"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"211"},{"groupId":"BG001","value":"229"},{"groupId":"BG003","value":"440"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"348"},{"groupId":"BG001","value":"349"},{"groupId":"BG003","value":"697"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"32"},{"groupId":"BG003","value":"64"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"527"},{"groupId":"BG001","value":"546"},{"groupId":"BG003","value":"1073"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"During the trial, it was learned that KRAS mutation predicted for lack of efficacy of EGFR antibodies; also studies showed no benefit from chemo combined with both Bevacizumab and an EGFR antibody. The trial was amended to 2 arms limited to KRAS wild type patients. Only confirmed and consented KRAS wild type patients were analyzed."}